Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

2012220 citationsReviewgold Open Access

Authors

These results from a large Phase 3 programme support the hypothesis that linagliptin may have CV benefits in patients with T2DM.

Good health and well-being

Published in: Cardiovascular Diabetology

Volume 11, Issue 1, pp. 3-3

Field-Weighted Citation Impact: 27.58